Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key ...

Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

FutureG Office is investing in cutting-edge, next-gen techIt has handed $28m in funding to Cohere Technologies for the ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...

Multi-Waveform Wireless Prototype Will Deliver Operational Aerial Surveillance and Response ISAC is a mission-first ...

Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12SOLANA BEACH, Calif., ...

AVXL rated Hold: strong $131.7M cash runway, but blarcamesine’s upside hinges on clearer efficacy and FDA approval.

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present ...